Project Grant R01HL173028
Award Date
1/1/25
Completion Date
12/31/29
Dollars Obligated
$835K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Boston, MA 02114, USA
Similar Awards
The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health, awarded a $165,080 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the Dana-Farber Cancer Institute (DFCI). The grant, which runs from September 1, 2024 to August 31, 2029, will support research to define the relationship between clonal hematopoiesis (CH) and inflammatory disease outcomes. The key goals are to: 1) Characterize the association between CH and...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $753,813 to Yale University to develop an innovative machine learning approach for predicting cardiovascular outcomes in patients with clonal hematopoiesis of indeterminate potential (CHIP). The key objectives are to: 1) Use convolutional neural networks on cardiac MRI data to accurately identify CHIP patients and predict future heart...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $735,085 Project Grant under the Cardiovascular Diseases Research federal grant program (CFDA 93.837) to Case Western Reserve University. The grant, which runs from December 5, 2024 to November 30, 2028, aims to investigate how modulating the Heat Shock Transcription Factor 1 (HSF1) protein can sustain or enhance the self-renewal and balanced lineage commitment of hematopoietic stem/progenitor cells, while preventing the progression...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $1,127,798 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), for the period of February 1, 2025 to January 31, 2032. The grant supports a comprehensive research program to understand the role of macrophages in preserving cardiovascular health, illuminate their contributions to cardiovascular disease (CVD), and...
This $827,665 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837) supports research to develop scalable methods for identifying causal genetic variants, relevant cell types, and target genes that influence cardiovascular disease (CVD) risk. The key products and services to be delivered include: Performing colocalization of CVD and blood cell trait genome-wide association studies (GWAS) to...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $686,640 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to The Trustees of Columbia University in the City of New York, doing business as the Health Sciences Division. The grant, titled "Finding and Pushing the Limits of Macrophage Efferocytosis in Atherosclerosis," aims to uncover new insights into therapeutic opportunities targeting macrophage efferocytosis (the clearance of dead cells) to mitigate the...
This $698,017 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI)'s Cardiovascular Diseases Research program (CFDA 93.837) supports the development of a cardiovascular disease (CVD) vaccine targeting the S100A9 protein and potentially PCSK9 cholesterol regulation. The University of California, San Diego (UCSD) is using the 4-year grant to: Develop S100A9-based vaccine candidates using plant virus-like particles and evaluate their ability to reduce S100A9 levels,...
This Project Grant award for $2,600,114 from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to evaluate the role of thiol isomerases (TIs) and oxidant stress in thrombus (blood clot) formation. The key research objectives are to: Determine how oxidants generated in disease states promote specific cysteine modifications in the TI protein disulfide isomerase (PDI), and how these oxidative changes to PDI...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research (CFDA 93.837) program, supports research on CAMK4 as a regulator of inflammation resolution and trained immunity in atherosclerosis. The primary aims are to explore how trained immunity impairs efferocytosis, a key process in resolving inflammation, and to investigate the role of CAMK4 in trained immunity development. The total award amount is $100,325, provided...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), totaling $528,179 and awarded on March 4, 2025, supports research to investigate the systemic effects of ischemia-induced reprogramming of monocytes to improve neovascularization in peripheral arterial disease (PAD) and critical limb ischemia (CLI). The key research goals are to: 1) determine if extracellular vesicles mediate the systemic...